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Abstract
Summary A 36-month observational study compared the
incidence of unaffected side hip fracture in Japanese female
osteoporosis patients with a history of hip fracture between
173 patients receiving risedronate and 356 risedronate-
untreated controls. New hip fractures were significantly less
frequent in the risedronate group, suggesting a preventive
effect in high-risk patients.
Introduction The purpose of this study was to investigate
the preventive effect of risedronate on second hip fracture
immediately following a first hip fracture in Japanese
female osteoporosis patients with unilateral hip fracture.
Methods We conducted a prospective matched cohort study
in 184 patients treated with risedronate and 445 patients not
receiving risedronate after discharge from hospital. Both
groups were followed-up for 36 months, and the incidence
of unaffected side hip fracture and the frequency of adverse
events were assessed.
Results Efficacy could be investigated in 173 patients from
the risedronate group and 356 patients from the control
group. Hip fracture was detected in 5 and 32 patients,
respectively. Kaplan–Meier estimates of the 36-month
fracture incidence were 4.3% in the risedronate group and
13.1% in the control group (P=0.010, log-rank test). The
hazard ratios (95% confidence intervals) obtained by
univariate and multivariate analysis were 0.310 (0.121–
0.796) and 0.218 (0.074–0.639), respectively, indicating a
significantly lower incidence of unaffected side hip fracture
in the risedronate group. Adverse events occurred in 38
patients (48 events) from the risedronate group and 94
patients (108 events) from the control group, with serious
adverse events in 21 patients (26 events) and 78 patients
(88 events), respectively.
Conclusions No significant differences were observed
between the two groups. The incidence of unaffected side
hip fracture was significantly lower in the risedronate
group. Accordingly, risedronate may have a preventive
effect on hip fracture in high-risk Japanese female
osteoporosis patients for fracture with a history of unilateral
hip fracture.
M. Osaki (*): T. Hashikawa:T. Norimatsu:K. Chiba:
H. Shindo
Department of Orthopaedic Surgery, Nagasaki University
Graduate School of Biomedical Sciences,
1-7-1 Sakamoto,
Nagasaki 852-8501, Japan
e-mail: mosaki@nagasaki-u.ac.jp
K. Tatsuki
Takeda Pharmaceutical Company Limited,
1-1, Doshomachi 4-Chome, Chuo-ku,
Osaka 540-8645, Japan
S. Motokawa
Department of Orthopaedic Surgery,
National Hospital Organization Nagasaki Medical Center,
Kubara 2-1001-1 Omura,
Nagasaki 856-8562, Japan
I. Furuichi
Department of Orthopaedic Surgery, Ureshino Medical Center,
2436, Ureshino-machi, Shimojuku, Ureshino-shi,
Saga 843-0393, Japan
Y. Doiguchi
Department of Orthopaedic Surgery, Nagasaki Rosai Hospital,
2-12-5. Setogoe, Sasebo-shi,
Nagasaki 857-0134, Japan
T. Hashikawa: T. Norimatsu: K. Aoyagi
Department of Public Health, Nagasaki University Graduate
School of Biomedical Sciences,
1-12-4 Sakamoto,
Nagasaki 852-8523, Japan
Osteoporos Int (2012) 23:695–703
DOI 10.1007/s00198-011-1556-7Keywords Bisphosphonate.Hip fracture.Matched cohort
study.Osteoporosis.Risedronate
Introduction
Osteoporosis is defined as “a skeletal disease characterized
by loss of bone strength susceptible to increased risk of
fracture”, which is frequent in women and the elderly [1].
According to the current WHO diagnostic criteria [2], the
number of osteoporosis patients in USA is estimated to be
5.3 million [3], while the 2006 Japanese guideline estimates
the number of Japanese patients as 7.8 to 11 million [4].
The objective of treating osteoporosis is to prevent the
occurrence of fracture. Among the fractures attributable to
osteoporosis, hip fracture has the most important influence
on survival, quality of life, and medical costs. The
worldwide incidence of hip fracture is expected to increase
from approximately 1.5 million in 1990 to 4.5–6.3 million
in 2050 [5, 6]. The number of hip fractures in Japan was
estimated to be 148,100 in 2007, and this has increased
every year since the start of investigation in 1987 [7].
Prior fracture is a risk factor for new fractures in addition
to sex, age, and low bone mineral density (BMD) [8]. In
particular, patients with a history of hip fracture may have
an increased risk of unaffected side hip fracture because of
excessive weight bearing on the opposite side while
walking due to anxiety about recurrence.
Current drug treatment for osteoporosis has made consider-
ableprogress.Risedronateisabisphosphonatethatisemployed
in patients with osteoporosis, which reduces bone resorption
and bone turnover by inhibiting osteoclast activity [9].
Risedronate has been shown to increase BMD [10, 11], and
to inhibit the occurrence of vertebral compression fractures
[12, 13] as well as hip fractures [14, 15] .B a s e do ns u c h
evidence, it is considered that risedronate is one of the most
effective treatments for osteoporosis currently available [16].
Only a few studies on the efficacy of risedronate for
inhibiting hip fracture in specific Japanese patient group
have been performed so far [17, 18]. In addition, although
patients with a history of hip fracture have a higher risk of
new hip fractures, a study has not been conducted in this
patient population. Accordingly, we conducted a prospec-
tive matched cohort study in Japanese osteoporosis patients
with a history of hip fracture.
Methods
Study design and subjects
This study was conducted in female Japanese patients at
Nagasaki University hospital and 16 affiliated institutions (17
institutions in total). The enrollment period was from July
2003 to June 2006, and the study finished in June 2009.
All patients who underwent hip fracture surgery at the
participating institutions and were discharged during the
enrollment period were tentatively enrolled by uploading data
to a web page. The enrollment items were sex, age, height,
body weight, body mass index (BMI), presence/absence of
osteoporosis, presence/absence of vertebral fracture, site of
hip fracture surgery, date of injury, date of hospitalization,
treatment of the fracture, address at the time of injury,
postoperative period, independence rating before injury,
independence rating at discharge, drug treatment for osteopo-
rosis at discharge, past history at discharge, complications at
discharge, BMD, and possibility/impossibility of outpatient
follow-up. The attending physician explained the purpose and
methods of this study to each patient. We specified Japanese
criteria for the diagnosis of osteoporosis according to the
diagnostic standard for primary osteoporosis (2000 revised
edition) of the Japanese Society for Bone and Mineral
Research [19]. The exclusion criteria were as follows: (1)
no diagnosis of primary osteoporosis according to the above
criteria, (2) bilateral hip fracture, (3) prior history of hip
fracture, (4) patients discharged death, and (5) patients who
could not be followed-up after discharge.
Out of the preliminary enrolled patients, those treated
with risedronate at the approved Japanese dose of 2.5 mg/
day (Benet® 2.5 mg; Takeda Pharmaceutical Co., Ltd,
Osaka, Japan) at the initial visit after discharge on the
judgment of the physician in charge were included in the
administration group. Following the initial outpatient visit
after discharge from hospital, patients were enrolled by
uploading the required data to the web page.
After enrollment of patients in the group receiving
risedronate, the patient enrollment center selected all of
the matching patients as candidates for the control group.
The demographic data and other items used for matching
the groups are listed in Appendix 1. Patients in the control
group were not being treated with any bisphosphonate
preparation and the required data was uploaded as the
control group to the web page (Fig. 1).
The duration of the study was 36 months from the initial
outpatient visit after discharge from hospital, and data from
case report forms were uploaded to the web page every
6 months. The items assessed included the presence/
absence of unaffected side hip fracture and the date of
occurrence, adverse events, compliance with medication,
other drugs for the treatment of osteoporosis, drugs for the
treatment of complications, other concomitant therapy,
independence rating, bone metabolism markers, BMD,
and new clinical fractures.
The study was discontinued if patients satisfied any of
the following criteria for discontinuation; failure to attend,
refusal of treatment, discontinuation of risedronate or
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only), starting treatment with a bisphosphonate (control
group only), and occurrence of adverse events. For the
discontinued/dropout patients, the presence/absence of
fractures until the discontinued/dropout date were deter-
mined. In addition, the incidence of unaffected side hip
fracture during the period from the discontinued/dropout
date to 3 years after the initial outpatient visit was
investigated separately.
This survey was a post-marketing surveillance conducted
according to the Japanese Good Post-Marketing Surveillance
Practice (GPMSP) and Good Post-Marketing Study Practice
(GPSP) ordinances. The GPMSP and GPSP ordinances
specify items that are to be strictly complied with in
order to achieve appropriate post-marketing surveillance
and studies of drugs. According to these ordinances, a
post-marketing survey is to be conducted in accordance
with the approved indications and during routine medical
practice. As described above, risedronate was adminis-
tered according to the judgment of the attending
physician and in compliance with the abovementioned
conditions. To minimize the resulting bias, demographic
factors showing significant intergroup differences were
adjusted by multivariate analysis.
Treatment
Patients in the risedronate group took a Benet® 2.5 mg
tablet orally once daily at the time of awakening with water
(approximately 180 mL). If administration of risedronate
was discontinued or switched to another bisphosphonate,
the study was discontinued.
Statistical analysis
All of the patients enrolled were analyzed for safety, while
those in whom the status of the unaffected side hip was
confirmed at least once after the start of the study were
assessedfor efficacy. Patientsdemographic factors (age, BMI,
site of hip fracture surgery, etc.) were totaled for each group,
and intergroup comparison was performed. The incidence of
unaffected side hip fracture was estimated by the Kaplan–
Meier method, and differences were investigated by the log-
ranktest. Univariateand multivariateanalysesweredonewith
known risk factors for hip fracture (age, and BMI [20])
and demographic factors showing significant intergroup
differences as the explanatory variables to estimate the
hazard ratios for unaffected side hip fracture after
adjustment for these variables. Adverse events were
totaled in each group, and intergroup differences were
investigated by using Fisher’s exact test. All statistical
analyses were performed with SAS 9.1.3 software. The
level of significance and the confidence interval were P≤
0.05 (bilateral) and 95% (bilateral), respectively.
Results
Characteristics of the patients and follow-up
Of the 2,051 patients who underwent hip fracture surgery
and following preliminary enrollment, 184 patients were
taking risedronate at the initial outpatient visit after
discharge. A total of 445 patients were matched with the
patients taking risedronate. Then, 11 patients from the
risedronate group and 89 patients from the control group
were excluded because it was impossible to follow-up after
initial visit, leaving 529 patients (173 in the risedronate
group and 356 in the control group) for efficacy analysis
(Fig. 1).
The age and BMI (mean ± standard deviation) at the time
of discharge were 80.2±7.9 years and 21.00±3.64 kg/m
2,
respectively, in the risedronate group versus 81.9±8.0 years
and 20.66±3.32 kg/m
2 in the control group. The site of hip
fracture surgery was either medial or lateral in nearly half of
the patients each, and the most frequent method of treatment
was surgical osteosynthesis. Concerning the treatment for
osteoporosis at the time of discharge from hospital, the use
of bisphosphonates was significantly more frequent in the
risedronate group (27.2%) than in the control group (2.5%)
(P<0.001). With regard to vitamin D3 administration, no
significant differences were observed between the two
groups at discharge or at the initial outpatient visit.
Fig. 1 Disposition of the patients. Of the 2,051 patients who
underwent preliminary enrollment, 1,142 patients were ineligible,
and 280 patients were excluded from enrollment for several reasons.
Among the rest, 184 patients were taking risedronate at the initial
outpatient visit after discharge. Four hundred forty-five patients were
matched with patients with taking risedronate. Then, 11 patients from
the risedronate group and 89 patients from the control group were
excluded because it was impossible to follow-up after initial visit,
leaving 529 patients (173 in the risedronate group and 356 in the
control group) for efficacy analysis
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Group P value
Risedronate
group
Control group
Number of patients 173 356
Age (at discharge) Mean (SD) 80.2 (7.9) 81.9 (8.0) P=0.004
BMI (at discharge) Mean (SD) 21.00 (3.64) 20.66 (3.32) P=0.636
Site of hip fracture Medial 95 (54.9%) 167 (46.9%) P=0.072
Lateral 77 (44.5%) 189 (53.1%)
Bilateral 1 (0.6%) 0 (0.0%)
Treatment Osteosynthesis 114 (65.9%) 248 (69.7%) P=0.327
Femoral head replacement 58 (33.5%) 102 (28.7%)
Conservative therapy 1 (0.6%) 6 (1.7%)
Drug treatment for osteoporosis at discharge Present 66 (38.2%) 72 (20.2%) P<0.001
Ca preparation 3 (1.7%) 5 (1.4%) P=0.720
VD3 preparation 16 (9.2%) 54 (15.2%) P=0.075
VK2 preparation 2 (1.2%) 4 (1.1%) P=1.000
Calcitonin preparation 3 (1.7%) 2 (0.6%) P=0.336
Female hormone
preparation
0 (0.0%) 0 (0.0%) –
Others 0 (0.0%) 4 (1.1%) P=0.309
Bisphosphonate
preparation
47 (27.2%) 9 (2.5%) P<0.001
Risedronate 46 (26.6%) 5 (1.4%) P<0.001
Alendronate 1 (0.6%) 3 (0.8%) P=1.000
Didronel 0 (0.0%) 1 (0.3%) P=1.000
Complications at discharge Present 132 (76.3%) 315 (88.5%) P<0.001
Cardiac disease 44 (25.4%) 129 (36.2%) P=0.014
Diabetes 14 (8.1%) 41 (11.5%) P=0.288
Hypertension 98 (56.6%) 215 (60.4%) P=0.451
Hyperlipidemia 24 (13.9%) 29 (8.1%) P=0.045
Dementia 31 (17.9%) 141 (39.6%) P<0.001
Parkinson’s disease 2 (1.2%) 16 (4.5%) P=0.070
Gastrointestinal disease 34 (19.7%) 77 (21.6%) P=0.650
Drug treatment for osteoporosis at the initial visit after
discharge
Present 34 (19.7%) 54 (15.2%) P=0.214
Ca preparation 7 (4.0%) 6 (1.7%) P=0.133
VD3 preparation 28 (16.2%) 45 (12.6%) P=0.284
VK2 preparation 0 (0.0%) 5 (1.4%) P=0.178
Calcitonin preparation 1 (0.6%) 4 (1.1%) P=1.000
Female hormone
preparation
0 (0.0%) 0 (0.0%) –
Others 0 (0.0%) 3 (0.8%) P=0.554
Independence rating at the initial visit after discharge Independent gait 21 (12.1%) 33 (9.3%) P=0.011
Cane walk 106 (61.3%) 176 (49.4%)
Walker 15 (8.7%) 58 (16.3%)
Wheelchair 31 (17.9%) 84 (23.6%)
Bedridden 0 (0.0%) 5 (1.4%)
BMI body mass index, SD standard deviation, Ca calcium, VD3 vitamin D3, VK2 vitamin K2
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difference between the two groups with respect to cardiac
disease (risedronate group: 25.4%; control group: 36.2%, P=
0.014), hyperlipidemia (13.9% versus 8.9%, P=0.045), and
dementia (17.9% versus 39.6%, P<0.001). With regard to
other drugs being taken for the treatment for osteoporosis
(excluding risedronate) at the initial outpatient visit after
discharge, no significant differences were observed between
the two groups. The independence rating was significantly
higher in the risedronate group (P=0.011) (Table 1).
Compliance
In the risedronate group, the compliance rate with treatment
was “90% or higher” throughout the study in most patients,
and this was a high level of compliance.
Incidence of unaffected side hip fracture
Unaffected side hip fracture occurred in 5 patients from the
risedronate group and 32 patients from the control group.
The 36-month incidence was estimated to be 4.3% in the
risedronate group and 13.1% in the control group, with a
significant difference between the two groups (P=0.010,
log-rank test). The hazard ratio calculated by univariate
analysis was 0.310, indicating a 69% decrease in the risk of
unaffected side hip fracture in the risedronate group
(Fig. 2).
Multivariate analysis was also done using age, BMI, and
demographic factors with significant intergroup differences
as explanatory variables, and the adjusted hazard ratio was
estimated to be 0.218, also indicating a significantly lower
risk of unaffected side hip fracture in the risedronate group
(P=0.006) (Table 2).
Bone mineral density
Bone mineral density of the lumbar spine (second to fourth
lumbar spine BMD) at the start of the study was 0.7105±
0.1834 (g/cm
2) in the risedronate group, and 0.6220±
0.1594 (g/cm
2) in the control group, showing no significant
difference between the two groups (P=0.110).
Adverse events
Adverse events occurred in 38 patients (20.7%, 48 events)
from the risedronate group and 94 patients (21.1%, 108
events) from the control group. These events were serious in
21 patients (11.4%, 26 events) from the risedronate group and
78 patients (17.5%, 88 events) from the control group. No
significantdifferenceswereobservedbetweenthetwogroups.
The most frequent adverse event in the risedronate group was
gastrointestinal disorders (13 events, 7.1%), and such disor-
ders were significantly (P< 0 . 0 0 1 )m o r ef r e q u e n tt h a ni nt h e
control group (three events, 0.7%).
Hip fracture occurred in 34 patients (7.6%) from the
control group, showing a significantly (P=0.002) higher
incidence than in the risedronate group (three patients,
1.6%) (Table 3).
Discussion
In this study, the incidence of unaffected side hip fracture was
comparedbetweenJapanesefemaleosteoporosispatientswho
werefollowed-upaftersurgeryforhipfracturewithorwithout
risedronate treatment. The incidence of unaffected side hip
fracture was significantly lower in the risedronate group than
thecontrolgroup,suggestingapreventiveeffectofrisedronate
on hip fracture in these high-risk patients.
According to recent reports [21, 22], the incidence of hip
fracture is decreasing in Europe and the USA. However, it
is anticipated that the worldwide incidence of hip fracture
will continue to increase considering the aging of the
population. For example, another study [23] has shown that
the incidence of hip fracture is still increasing in Japan.
Taking the speed of population aging into consideration,
prevention of hip fracture is an urgent issue for Japanese
health policy.
Fig. 2 Kaplan–Meier curves for the occurrence of unaffected side hip
fracture (efficacy analysis set). Unaffected side hip fracture occurred
in five patients from the risedronate group and 32 patients from the
control group. The 36-month incidence was estimated to be 4.3% in
the risedronate group and 13.1% in the control group, with a
significant difference between the two groups (P=0.010, log-rank
test). The hazard ratio calculated by univariate analysis was 0.310,
indicating a 69% decrease in the risk of unaffected side hip fracture in
the risedronate group
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with the primary endpoint of hip fracture, i.e., the HIP
study [14] and the HORIZON study evaluating the effect of
zoledronate [24], and both were placebo-controlled studies.
Although there is sufficient evidence of a preventive effect
on hip fracture for various drugs, adequate information is
not available about their relative efficacy and safety [16].
This study showed that risedronate can prevent new hip
fractures in patients with a history of hip fracture, i.e., a
high-risk population. It provides useful information for
determining the management of osteoporosis.
A subgroup analysis of patients with osteoporosis
aged 70 years or older [15] from the HIP study evaluated
the efficacy of risedronate for preventing hip fracture [14]
and demonstrated that the 36-month incidence of hip
fracture was 7.4% in the placebo group versus 3.8% in the
risedronate group, with the relative risk being 0.54. In the
present study, the 36-month incidence of unaffected side
hip fracture was 13.1% in the control group versus 4.3% in
the risedronate group (hazard ratio: 0.31), indicating a
similar preventive effect, although the incidence of
fracture was higher in our two groups. These results
suggest that risedronate can prevent new fractures even in
patients in the high-risk groups with the history of fracture
caused by osteoporosis. It is likely that the higher
incidence of fracture in the present study can be attributed
to the enrollment of patients who had already suffered
from hip fracture.
Regarding the efficacy of risedronate for inhibiting hip
fracture in Japanese population, the Sato Y et al. reported
the preventive effect of risedronate and ergocalciferol
plus calcium supplementation in Japanese women with
Alzheimer’sd i s e a s e[ 17]. They also reported the preven-
tive effect of risedronate in Japanese men after stroke [18].
Although they presented the preventive effect of risedro-
nate on hip fracture, the objective of these studies are
limited to the specific Japanese patient group. In addition,
although patients with a history of hip fracture have a
Table 2 Cox regression analysis of unaffected-side hip fracture (efficacy analysis set)
Univariate Multivariate
Explanatory variable Category N HR estimate (95% CI) P value HR estimate (95% CI) P value
Group Control group 356 Reference Reference
Risedronate group 173
0.310 (0.121, 0.796)
0.015
0.218 (0.074, 0.639)
0.006
Age (at discharge) ≤69 34 Reference Reference
70–79 151
0.311 (0.084, 1.160)
0.082
0.303 (0.077, 1.196)
0.088
80–89 273
1.060 (0.369, 3.041)
0.914
0.993 (0.309, 3.185)
0.990
≥90 71
0.319 (0.058, 1.743)
0.187
0.278 (0.045, 1.725)
0.169
BMI (at discharge) Lower than 20 217 Reference Reference
20 or higher to lower than 25 255
0.474 (0.237, 0.947)
0.035
0.507 (0.250, 1.029)
0.060
25 or higher 57
0.462 (0.138, 1.549)
0.211
0.539 (0.154, 1.891)
0.334
Drug treatment for osteoporosis (at discharge) Nonuse 391 Reference Reference
Use 138
0.902 (0.436, 1.864)
0.780
0.869 (0.328, 2.305)
0.778
Bisphosphonate therapy (at discharge) Nonuse 473 Reference Reference
Use 56
1.144 (0.445, 2.937)
0.780
2.728 (0.695, 10.706)
0.150
Complications (at discharge) Absent 82 Reference Reference
Present 447
0.909 (0.379, 2.178)
0.830
0.850 (0.303, 2.384)
0.758
Cardiac disease (at discharge) Absent 356 Reference Reference
Present 173 1.092 (0.556, 2.145) 0.798 0.969 (0.468, 2.010) 0.933
Dementia (at discharge) Absent 357 Reference Reference
Present 172
1.555 (0.807, 2.999)
0.187
1.522 (0.714, 3.244)
0.277
Independence rating (at the initial visit) Independent/stick 336 Reference Reference
Walker 73
0.389 (0.092, 1.636)
0.198
0.296 (0.069, 1.275)
0.102
Wheelchair/bedridden 120
1.036 (0.470, 2.284)
0.929
0.872 (0.369, 2.060)
0.755
BMI body mass index, HR hazard ratio, CI confidence interval
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conducted in this patient population. This is the first study
conducted a prospective matched cohort study in Japanese
osteoporosis patients with a history of hip fracture.
Patients on treatment with risedronate at the time of their
initial visit and at the time of discharge were enrolled as the
risedronate group. In the control group, patients receiving
bisphosphonates at the time of discharge had discontinued
treatment by the time of their initial visit. The patients who
suffered a fracture even though they were on treatment with
bisphosphonates might have been at higher risk.
In the present study, there was no significant difference in
the incidence of adverse events between the risedronate group
and the control group. However, gastrointestinal disorders
were significantly more frequent in the risedronate group
(7.1%). Gastrointestinal disorders are a well-known adverse
effect of bisphosphonates [25], and the results obtained in
this study are considered to be within the expected range for
Japanese patients based on previous data [26].
Limitations
This study was a prospective cohort study without
randomization and blinding. Accordingly, comparability
between the risedronate group and the control group was
not complete. Therefore, demographic factors showing
significant intergroup differences were adjusted by multi-
variate analysis to their influence on the results. Neverthe-
less, it is necessary to recognize this limitation when our
results are interpreted.
Patients on treatment with risedronate at the time of their
initial visit and at the time of discharge were enrolled as the
risedronate group. In the control group, patients receiving
bisphosphonates at the time of discharge had discontinued
treatment by the time of their initial visit. The patients who
suffered a fracture even though they were on treatment with
bisphosphonates might have been at higher risk.
Future prospects
In order to provide appropriate therapy for osteoporosis, it is
necessary to better define the characteristics of each drug, and
large-scale long-term follow-up is required for accumulation
of a sufficient number of events because of the relatively low
incidence of hip fracture. A prospective international cohort
study (Global Longitudinal Study of Osteoporosisin Women)
[27] was started in 2006, with the aim of following
approximately 60,000 women aged 55 or older for 5 years.
Such efforts are expected to clarify the characteristics of
drugs for osteoporosis therapy, including risedronate.
Table 3 Adverse events (safety analysis set)
Adverse event Group P value
(1% or higher in either group) Risedronate group Control group (Fisher’s exact test)
No. of patients 184 445
Number of patients with adverse events 38 (20.7%) 94 (21.1%) P=1.000
Number of adverse event 48 108
Number of patients with serious adverse events 21 (11.4%) 78 (17.5%) P=0.070
Number of serious adverse events 26 88
Cardiac disorders 2 (1.1%) 3 (0.7%) P=0.633
Gastrointestinal disorders 13 (7.1%) 3 (0.7%) P<0.001
Epigastric pain 2 (1.1%) 0 (0.0%) P=0.085
Constipation 3 (1.6%) 1 (0.2%) P=0.078
Gastritis 3 (1.6%) 0 (0.0%) P=0.025
General disorders and administration site conditions 3 (1.6%) 7 (1.6%) P=1.000
Death 1 (0.5%) 7 (1.6%) P=0.448
Infections and infestations 3 (1.6%) 9 (2.0%) P=1.000
Pneumonia 1 (0.5%) 6 (1.3%) P=0.680
Injury, poisoning and procedural complications 11 (6.0%) 60 (13.5%) P=0.006
Hip fracture 3 (1.6%) 34 (7.6%) P=0.002
Radius fracture 2 (1.1%) 1 (0.2%) P=0.206
Spinal compression fracture 2 (1.1%) 9 (2.0%) P=0.523
Musculoskeletal and connective tissue disorders 3(1.6%) 3 (0.7%) P=0.365
Nervous system disorders 4 (2.2%) 4 (0.9%) P=0.241
Dementia 2 (1.1%) 0 (0.0%) P=0.085
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Appendix 1: matching of the groups
Matching parameters are shown below.Matchingwas regarded
as satisfactory when all of the items for complete matching and
three or more items for partial matching were obtained.
1. Items for complete matching (matching of all 3 items is
required)
■ Age: (1) 69 years or younger (2) 70–79 years (3)
80–89 years (4) 90 years or older
■ Site of hip fracture: (1) lateral (2) medial
■ Independence rating at the time of discharge: (1)
independent walking or use of a cane (2) walker
(3) wheelchair or bedridden
2. Items required for partial matching (matching of three
or more items was required)
■ Height: (1) less than 140 cm (2) 140 cm or more
■ Body weight: (1) less than 50 kg (2) 50 kg or more
■ Postoperative period: (1) less than 3 months (2)
3 months to less than 6 months (3) 6 months or more
■ Presence/absence of vertebral body fracture: (1)
absent (2) present (3) unknown
■ Independenceratingbeforeinjury:(1)independent
walking or use of a cane (2) walker (3) wheelchair or
bedridden
■ Outpatient follow-up: (1) possible (2) impossible
(3) unknown
References
1. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus
Statement 2000 March 27–29; 17: 1–45
2. Kanis JA, McCloskey EV, Johansson H et al (2008) A reference
standard for the description of osteoporosis. Bone 42:467–475
3. Looker AC, Melton LJ, Harris TB et al (2009) Prevalence and
trends in low femur bone density among older US adults:
NHANES 2005-2006 compared with NHANES III. J Bone Miner
Res 25(1):64–7
4. Guidelines for prevention and treatment of osteoporosis. (2006)
ed. Life Science Publishing Co., Ltd
5. Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the
elderly: a world-wide projection. Osteoporos Int 2:285–289
6. Gullberg B, Johnell O, Kanis JA (1997) World-wide projections
for hip fracture. Osteoporos Int 7:407–413
7. Orimo H, Yaegashi Y, Onoda T (2009) Hip fracture incidence in
Japan: estimates of new patients in 2007 and 20-year trends. Arch
Osteoporos 4:71–77
8. Prevention and management of osteoporosis. Report of a WHO
scientific group. WHO Technical Report Series 921, 2003
9. Geusens P, McClung M (2001) Review of risedronate in the
treatment of osteoporosis. Expert Opin Pharmacother 2:2011–
2025
10. Fogelman I, Ribot C, Smith R et al (2000) Risedronate reverses
bone loss in postmenopausal women with low bone mass: results
from a multinational, double-blind, placebo-controlled trial.
BMD-MN Study Group. J Clin Endocrinol Metab 85:1895–1900
11. Fukunaga M, Kushida K, Kishimoto H et al (2002) A comparison
of the effect of risedronate and etidronate on lumbar bone mineral
density in Japanese patients with osteoporosis: a randomized
controlled trial. Osteoporos Int 13:971–979
12. Harris ST, Watts NB, Genant HK et al (1999) Effects of
risedronate treatment on vertebral and nonvertebral fractures in
women with postmenopausal osteoporosis: a randomized con-
trolled trial Vertebral Efficacy With Risedronate Therapy (VERT)
study group. JAMA 282(14):1344–1352
13. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized
trial of the effects of risedronate on vertebral fractures in women
with established postmenopausal osteoporosis. Vertebral Efficacy
with Risedronate Therapy (VERT) study group. Osteoporos Int
11:83–91
14. McClung MR, Geusens P, Miller PD et al (2001) Effect of
risedronate on the risk of hip fracture in elderly women. Hip
Intervention Program Study Group. N Engl J Med 344:333–340
702 Osteoporos Int (2012) 23:695–70315. Masud T, McClung M, Geusens P (2009) Reducing hip fracture
risk with risedronate in elderly women with established osteopo-
rosis. Clin Interv Aging 4:445–449
16. MacLean C, Newberry S, Maglione M et al (2008) Systematic
review: comparative effectiveness of treatments to prevent
fractures in men and women with low bone density or
osteoporosis. Ann Intern Med 148:197–213
17. Yoshihiro S, Tomohiro K, Kei S et al (2005) The prevention of hip
fracture with risedronate and ergocalciferol plus calcium supple-
mentation in elderly women with Alzheimer disease. Arch Inter
Med 165:1737–1742
18. Yoshihiro S, Jun I, Tomohiro K et al (2005) Risedronate sodium
therapy for prevention of hip fracture in men 65 years or older
after stroke. Arch Inter Med 165:1743–1748
19. Investigational Committee for Osteoporosis Diagnosis Standard,
Japanese Society for Bone and Mineral Research (2001) Diagno-
sis standard for primary osteoporosis (2000 revised edition). J Jpn
Soc Bone Miner Res 8:76–82
20. De Laet C, Kanis JA, Odén A et al (2005) Body mass index as a
predictor of fracture risk: a meta-analysis. Osteoporos Int
16:1330–1338
21. Chevalley T, Guilley E, Herrmann FR et al (2007) Incidence of
hip fracture over a 10-year period (1991-2000): reversal of a
secular trend. Bone 40:1284–1289
22. Melton LJ 3rd, Kearns AE, Atkinson EJ (2009) Secular trends
in hip fracture incidence and recurrence. Osteoporos Int
20:687–694
23. Hagino H, Furukawa K, Fujiwara S et al (2009) Recent trends in
the incidence and lifetime risk of hip fracture in Tottori, Japan.
Osteoporos Int 20:543–548
24. Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007)
Zoledronic acid and clinical fractures and mortality after hip
fracture. N Engl J Med 357:1799–1809
25. Peter CP, Kindt MV, Majka JA (1998) Comparative study of
potential for bisphosphonates to damage gastric mucosa of rats.
Dig Dis Sci 43:1009–1015
26. Kushida K, Kishimoto H et al (2002) Efficacy and safety of long-
term treatment with risedronate in patients with osteoporosis and
osteopenia. Osteoporos Jpn 10:85–97, in Japanese
27. Hooven FH, Adachi JD, Adami S et al (2009) The Global
Longitudinal Study of Osteoporosis in Women (GLOW): rationale
and study design. Osteoporos Int 20:1107–1116
Osteoporos Int (2012) 23:695–703 703